Pharmaceuticals

Recently, the US Food and Drug Administration (FDA) stated that it will not be able to arrive at a decision regarding MannKind Corporation's (MNKD) inhaled insulin candidate, Afrezza, by December 29, 2010 as announced previously. The US regulatory body stated that it will need approximately 4...

King Pharmaceuticals Inc. (KG) and partner Pain Therapeutics Inc. (PTIE) recently announced that they have resubmitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for their pain candidate Remoxy. Remoxy has been developed using Durect Corporation's (DRRX) ORADUR...

Cephalon Inc. (CEPH) recently announced that it no longer intends to pursue for the approval of Nuvigil for the treatment of patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel. The company arrived at this decision following the receipt of a second...

King Pharmaceuticals Inc. (KG) and partner Pain Therapeutics Inc. (PTIE) recently announced that they have resubmitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for their pain candidate Remoxy. Remoxy has been developed using Durect Corporation's (DRRX) ORADUR...

Recently, the US Food and Drug Administration (FDA) stated that it will not be able to arrive at a decision regarding MannKind Corporation's (MNKD) inhaled insulin candidate, Afrezza, by December 29, 2010 as announced previously. The US regulatory body stated that it will need approximately 4...

Wedbush has increased its price target on the following companies: Heartware (NASDAQ: HTWR) from $80 to $100. Riverbed Technology (NASDAQ: RVBD) from $34 to $40. Amarin (NASDAQ: AMRN) from $7 to $10. Foot Locker (NYSE: FL) from $22 to $23.

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced the acquisition of Sucampo AG (SAG) and its wholly-owned subsidiary, Sucampo AG Japan (SAGJ), from Ryuji Ueno, M.D., Ph.D., Ph.D., and Sachiko Kuno, Ph.D., co-founders and majority shareholders of Sucampo Pharmaceuticals, Inc. (SPI). The...

Over a week ago, InterMune (NASDAQ: ITMN) received a positive opinion from the EMA for Pirfenidone, a positive opinion for approval of Esbriet in the European Union. On that news, InterMune gained over 130% within a day, not to mention receiving an upgrade by Robert Baird a few days later....

Shares of Depomed, Inc. (Nasdaq: DEPO) are trading up 6.7% at $6.40 per share during the Tuesday afternoon trading session. The day's trading range for shares of Depomed, Inc has been between $6.16 and a 52-week high of $6.43 per share. Analysts covering Depomed, Inc. (DEPO) stock give it a...

Cusick's Corner After the market's tight range yesterday and now again today, market watchers are taking notice of volatility's move to the upside -- specifically the VIX popping from 16 to 18. This is a little unusual considering the light volume, tight range and the offensive sectors, i.e. XLF,...

US drug sector traded mixed, with the NYSE Arca Pharmaceutical Index (DRG) gaining about 0.25% and the NYSE Arca Biotechnology Index (BTK) losing about 0.35%. Shares of Biosante Pharmaceuticals Inc (NASDAQ: BPAX) dipped about 17.50% after the company announced its plans to raise $18 million in...

Let's put our technical analysis hats back on today. On Thursday, I introduced you to trading ranges, breakouts, and breakdowns. We'll take this analysis one step further today and look at six important technical patterns. These all require a basic understanding...

Let's put our technical analysis hats back on today. On Thursday, I introduced you to trading ranges, breakouts, and breakdowns. We'll take this analysis one step further today and look at six important technical patterns. These all require a basic understanding...

Sierra Wireless Inc (NASDAQ: SWIR) shares reached $15.04 to create a new 52-week high, before falling to $15.02, representing a 1.83% gain. SWIR's trailing-twelve-month revenue is $627.12 million. Depomed Inc (NASDAQ: DEPO) shares rose 5.00% to touch a new 52-week high of $6.30. DEPO's shares have...